MACROGENICS INC: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC amended its Schedule 13G stake filing for MacroGenics Inc., disclosing the change to the SEC under accession number 0001172661-26-005245. The filing updates the investment firm's reported position in the clinical-stage biopharmaceutical company, though the headline disclosure did not specify the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors and are closely watched for signals about institutional conviction in small-cap biotech names. Investors will look to the full filing for Armistice's updated ownership percentage and any change in shares held.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, MacroGenics Inc